Media stories about AnaptysBio (NASDAQ:ANAB) have trended somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AnaptysBio earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 44.792098377696 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
AnaptysBio (NASDAQ ANAB) opened at $126.45 on Friday. The stock has a market cap of $3,110.00 and a P/E ratio of -83.74. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77. AnaptysBio has a 1-year low of $18.15 and a 1-year high of $132.46.
Several equities research analysts have recently commented on ANAB shares. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target for the company in a research report on Friday, November 10th. SunTrust Banks lifted their price target on shares of AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a research report on Thursday. Robert W. Baird reiterated a “buy” rating and set a $144.00 price target (up previously from $81.00) on shares of AnaptysBio in a research report on Friday, January 19th. Wedbush reiterated a “positive” rating and set a $82.00 price target (up previously from $75.00) on shares of AnaptysBio in a research report on Tuesday, November 7th. Finally, ValuEngine upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $107.11.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.